[ad_1]
Two academics from the Institute of Biomedical Sciences (ICBM) of the University of Chile will conduct an international study on Chagas Disease funded by the European Union (EU) for three years, according to from the sources of the aforementioned university. [19659002LesDrsWernerAptetInésZulantayconcentrerontleurstravauxsurladéterminationdesmarqueursgénétiquesd'ungroupedepatientsdesrégionsendémiquesduChilietdelaBolivieafind'évaluerlasusceptibilitégénétiqueàl'infectionetsaréponseautraitementLamaladiedeChagasquitoucheplusde120000personnesauChiliestconsidéréeparl'Organisationmondialedelasanté(WHO)parmilesdixmaladies"neglected"danslemonde
According to & # 39; WHO, in the world there are 6 and 7 million infected " Trypanosoma cruzi ", the parasite that causes the disease, which is distributed in 21 countries of Latin America, transmitted mainly through the feces or urine of the insect known as vinchuca
. Chile's Francisco Rotthammer and Werner Apt, in 1988, showed that a group of infected people, belonging to the Diaguita ethnic group of the Elqui Valley, in the north of the country, were the only ones not to not show cardiac compromise, the leading cause of death. this type of patients. According to Dr. Apt, the study was one of the first at the international level where the hypothesis was emitted that the pathogenesis of this parasitosis was not centered solely on the transmitting parasite, but also on the genetic characteristics of the infection.
"In any infection, there is an interaction between the infectious agent, the host and the environment." If we badyze the parasite, we have not shown why the damage occurs. We have to look for the answer in humans to see if, genetically, Chagas disease is more serious than others, "he explained. "Now, we want to study whether there is a genetic marker that allows us to determine which people will develop heart disease and who will not," he said about the new study. context of the migratory phenomenon of recent years. The initiative represents a new framework for scientific research between the two continents and for Dr. Zulantay, the efforts of developed countries and global institutions "represent a fundamental shift in the struggle to mitigate the impacts of neglected health problems" . [19659002"LamaladiedeChagbad'estmondialiséeetcelasignifiequ'ilyaplusderessourcespouryfairefacepourl'Europec'estunepathologieimportéecommeconséquencedel'immigrationmaisjusqu'àprésentcequenousavonsvuc'estquemoinsde1%despersonnesNousespéronsqueceschiffresserontmodifiésàcourtterme"didildéclaréLeséquipesquicomposentl'equiped'étudesontdirigéesparl'UniversitédeHeidelberg(Germany)laFacultédemédecinedel'UniversitéduChilil'Institutnationaldesmaladiesinfectieusesd'Italieetl'UniversitédeSanSimondeBolivie[19659002LesdocteursAptetZulantaytravaillentdansleProgrammedeBiologieMoléculaireetCellulairedel'ICBMetcommeprofesseursdelaFacultédeMédecinedel'UduChilietontunelongueexpérienced'étudedelamaladiedanslaRégiondeCoquimbo(north)Cesdernièresannéesilssesontconcentréssurlarecherchederéponsesàl'interactionentreleparasitetransmetteuretl'hôtehumaindansleszonesendémiquesdecettepartiedupays[19659002]Salt Dr. Apt, the evaluation of genetic markers has two objectives: First, evaluate the relationship of certain genotypes with the cardiac involvement of the disease and second, if genetically we can say that there is some patients more likely to have side effects or greater tolerance to drugs. "In the interaction of the parasite with the human being, many factors influence both parties and perhaps still others that we do not know yet." Early investigations of the disease began by the badysis of the parasite. ", Explains
In this context, the purpose of the study is to understand why some people remain asymptomatic for life, or have very few clinical manifestations, while others develop the worst complications, such as than heart complications. The results of the study will help guide future research toward finding personalized treatments for the disease. "If we had to know which patients are going to have heart disease, we can intervene with treatment at an early stage," said Apt.
[ad_2]
Source link
